AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 61 min read$NTRA

Chapman Steven Leonard sold $510K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 2,351 shares of Natera, Inc. (NTRA) at $217.04 ($0.51M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but 10b5-1 plans typically weaken the inference about near-term fundamentals.

02

Market read

Disclosed insider selling may cause minor sentiment noise, but the 10b5-1 structure suggests limited new information content.

03

What to watch

The filing does not indicate whether other insiders or institutions are buying/selling, nor does it quantify total insider net activity around the same period.

Relevance 6/10Novelty 4/10Timing: SEC Form 4 filed June 5 for a sale executed June 4

Background

SEC Form 4 insider transaction: officer/director open-market sale by Natera CEO and president; includes a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and president Chapman Steven Leonard sold $510.3K of NTRA shares via an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.

Evidence & confidence

This is a routine Form 4 transaction with explicit 10b5-1 pre-arrangement, providing limited incremental fundamental insight.

Market effects

Sector

Minimal; this is company-specific insider activity without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    US-listed company whose CEO/president sold shares; transaction disclosed via SEC Form 4.

  • insider
    Chapman Steven Leonard

    CEO and president of Natera who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min